Dr. Daniel Ortega
Funding : European Science Foundation.TD Pilot COST Action TD1402
Duration: 2014 - 2018
In recent years, the emerging field of nanotechnology has paved its way into cancer treatment procedures with the use of nanoparticles for contrast media and therapeutic agents. The combination of conventional cancer therapies with nanotechnologies has shown to be promising in individual clinical studies and bears an enormous potential for the treatment individualisation tailored according to the patients needs.
This COST Action aims at teaming experienced scientists and young researchers from nanophysics, chemical sciences and medicine for improving the knowledge of combined cancer therapies. Particular attention will be paid to the increase of the radiotherapy efficiency and its combination with magnetic hyperthermia. These new findings, obtained under the coordination framework of this action, will results in a better dose optimisation confining cell damage to tumour regions only, under concurrent exploitation of sophisticated radio-surgical tools already available in hospitals. Furthermore, proper dissemination of scientific results to the broad public and possible stakeholders is another important concern of this action.
The improved knowledge resulting from the proposed coordinated, target-oriented interdisciplinary exchange will encourage industrial partners to produce a new generation of magnetic nanoparticles suitable for diagnosis, chemotherapy, radiotherapy and magnetic hyperthermia. Promoting the application of combined cancer treatments will contribute to a better individualised treatment planning for cost-efficient cancer therapies covered by state health insurances.http://www.cost.eu/COST_Actions/TDP/Actions/TD1402